Innovative, customized solutions
An Introduction
Translution Capital is a Nordic Corporate Finance house, which devises and executes innovative, customized solutions to our clients’ most challenging issues. Our services are based on extensive experience from leading Investment Banks.
Our operation is independent and free of any potential conflict of interest inherent within large multi-product financial institutions.
Identifying and quantifying clients’ financial resources
Strategic Financial Advisory
Transaction Solutions
Translution Capital initiates and participates in a high number of transactions annually. We offer a strategic financial advisory platform with a prime focus at trade sales alongside equity and debt based fund raisings.
Optimizing value
We factor in both confidentiality and the need to ensure competition during a sales process. Our daily dialogue with prospective investors allows us to anticipate issues that are important to the success of any transaction.
Financing solutions
Translution Capital devises and executes customized transaction solutions fully subject to our clients’ financial and strategic objectives and regardless of sector, size and situation.
Identifying value
Translution Capital operates and executes auction processes with prospective investors and buyers on a high clock speed to enforce the best possible transaction outcome for our clients.
SELECTED TRANSACTIONS
|
Transaction Size: |
DKK 14.7m |
|
Company Name: |
Cessatech A/S |
|
Closing: |
November 2022 |
|
Investor: |
Broad range of investors |
|
TC Advisory: |
Translution Capital acted as financial advisor to Cessatech A/S (Publ.) in a secured rights issue |
|
Transaction Size: |
NA |
|
Company Name: |
MME Nordic A/S |
|
Closing: |
June 2022 |
|
Acquirer: |
Blue Equity |
|
TC Advisory: |
Translution Capital acted as financial advisor to Blue Equity in connection with the add-on acquisition of the MedTech company MME Nordic A/S |
|
Transaction Size: |
DKK 108m |
|
Company Name: |
Medtrace Pharma A/S |
|
Closing: |
May 2022 |
|
Investor: |
ATP, BankInvest and Swisscanto |
|
TC Advisory: |
Translution Capital acted as financial advisor to Medtrace Pharma A/S in relation to their tranche II capital raise led by ATP, BankInvest and Swisscanto |
|
Transaction Size: |
SEK 56.7m |
|
Company Name: |
Bawat Water Technologies AB |
|
Closing: |
March 2022 |
|
Investor: |
Private and institutional investors |
|
TC Advisory: |
Translution Capital acted as exclusive financial advisor to Bawat Water Technologies AB in their IPO to private and institutional investors |
|
Transaction Size: |
NA |
|
Company Name: |
Moscord Pte.Ltd |
|
Closing: |
February 2022 |
|
Investor: |
Consortium of international institutional and strategic investors |
|
TC Advisory: |
Translution Capital acted as sole financial advisor to Moscord Pte.Ltd in securing their new funding round |
|
Transaction Size: |
NA |
|
Company Name: |
I Am Drinks ApS |
|
Closing: |
January 2022 |
|
Investor: |
REKOM Group A/S and Spritfabrikken Danmark ApS |
|
TC Advisory: |
Translution Capital acted as financial advisor to the selling shareholders of I Am Drinks ApS on the trade sale of the company |
|
Transaction Size: |
EUR 11m |
|
Company Name: |
Diok Real Estate AG |
|
Closing: |
December 2021 |
|
Investor: |
Collector Bank |
|
TC Advisory: |
Translution Capital acted as financial advisor to Diok Real Estate AG securing a funding package of EUR 11 million |
|
Transaction Size: |
SEK 509m |
|
Company Name: |
CombiGene AB |
|
Closing: |
November 2021 |
|
Investor: |
Spark Therapeutics, a company within the Roche Group |
|
TC Advisory: |
Translution Capital acted as financial advisor to CombiGene AB (publ.) in a deal securing a total funding package of up to SEK 509 million |
|
Transaction Size: |
SEK 44m |
|
Company Name: |
Expres2ion Biotech |
|
Closing: |
October 2021 |
|
Investor: |
Private and institutional investors |
|
TC Advisory: |
Translution Capital acted as financial advisor to Expres2ion Biotechnologies (publ.) in a new issue to private and institutional investors |
|
Transaction Size: |
Non-disclosed |
|
Company Name: |
CRisk Software ApS |
|
Closing: |
September 2021 |
|
Investor: |
Brady Technologies Limited, backed by private equity firm, Hanover Investors |
|
TC Advisory: |
Translution Capital acted as financial advisor to the selling shareholders of CRisk Software ApS on the trade sale of the company |
|
Transaction Size: |
SEK 308m |
|
Company Name: |
Allarity Therapeutics A/S |
|
Closing: |
August 2021 |
|
Investor: |
Broad range of investors |
|
TC Advisory: |
Translution Capital acted as financial advisor to Allarity Therapeutics A/S (Publ.) in a secured rights issue |
|
Transaction Size: |
SEK 150m |
|
Company Name: |
Biosergen AB |
|
Closing: |
June 2021 |
|
Investor: |
Private and institutional investors |
|
TC Advisory: |
Translution Capital acted as financial advisor to Biosergen AB in their IPO to private and institutional investors |
|
Transaction Size: |
Non-disclosed |
|
Company Name: |
Bawat A/S |
|
Closing: |
June 2021 |
|
Investor: |
Institutional and HNI investors |
|
TC Advisory: |
Translution Capital acted as sole financial advisor to Bawat A/S in relation to their fund raise led by selected institutional and HNI investors |
|
Transaction Size: |
SEK 39m |
|
Company Name: |
Expres2ion Biotech |
|
Closing: |
May 2021 |
|
Investor: |
Private and institutional investors |
|
TC Advisory: |
Translution Capital acted as financial advisor to Expres2ion Biotechnologies (publ.) in a new issue to private and institutional investors |
|
Transaction Size: |
DKK 180m |
|
Company Name: |
Medtrace Pharma A/S |
|
Closing: |
May 2021 |
|
Investor: |
ATP, BankInvest and Swisscanto |
|
TC Advisory: |
Translution Capital acted as financial advisor to Medtrace Pharma A/S in relation to their capital raise led by ATP, BankInvest and Swisscanto |
|
Transaction Size: |
Non-disclosed |
|
Company Name: |
Lamor Corporation AB |
|
Closing: |
April 2021 |
|
Investor: |
Institutional investors |
|
TC Advisory: |
Translution Capital acted as sole financial advisor to Lamor Corporation AB in relation to their fund raise led by selected institutional investors |
|
Transaction Size: |
DKK 150m |
|
Company Name: |
Plant Protein Venture |
|
Closing: |
March 2021 |
|
Lenders: |
Institutional investors |
|
TC Advisory: |
Translution Capital acted as financial advisor together with Nordic Investment Partners to secure total project financing |
|
Transaction Size: |
EUR 3m |
|
Company Name: |
Akvila Cutlery Oy |
|
Closing: |
February 2021 |
|
Lenders: |
Institutional investors |
|
TC Advisory: |
Translution Capital acted as sole financial advisor to Akvila Cutlery Oy in securing EUR 3m in debt financing |
|
Transaction Size: |
Non-disclosed |
|
Company Name: |
Bizbrains |
|
Closing: |
January 2021 |
|
Investor: |
VækstPartner Kapital |
|
TC Advisory: |
Translution Capital acted as sole financial advisor to Bizbrains in relation to the sale of a minority stake to VækstPartner Kapital |
|
Transaction Size: |
SEK 216m |
|
Company Name: |
Expres2ion Biotech |
|
Closing: |
November 2020 |
|
Investor: |
NYIP |
|
TC Advisory: |
Translution Capital acted as financial advisor to Expres2ion Biotechnologies (publ.) in a fully secured rights issue, with a directed issue to selected institutional investors |
|
Transaction Size: |
Non-disclosed |
|
Company Name: |
Sigma Estimates |
|
Closing: |
October 2020 |
|
Acquirer: |
EG A/S |
|
TC Advisory: |
Translution Capital acted as exclusive financial advisor to the owners of Sigma Estimates in relation to a trade sale of the company to EG |
|
Transaction Size: |
USD 182m |
|
Company Name: |
Margins Group |
|
Closing: |
August 2020 |
|
Investor: |
Institutional investors |
|
TC Advisory: |
Translution Capital acted as exclusive financial advisor to the owners of Margins Group on a USD 182m refinancing facility led by Institutional investors |
|
Transaction Size: |
DKK 10m |
|
Company Name: |
Scape Technologies |
|
Closing: |
May 2020 |
|
Investor: |
Institutional investors |
|
TC Advisory: |
Translution Capital advised the Danish manufacturer of industrial robots, Scape Technologies, securing a temporary loan facility |
|
Transaction Size: |
SEK 30m |
|
Company Name: |
Endomines |
|
Closing: |
April 2020 |
|
Lenders: |
Institutional investors & selected HNI’s |
|
TC Advisory: |
Translution Capital acted as financial advisor to Endomines in a short-term loan facility from Institutional investors and selected HNI’s |
|
Transaction Size: |
DKK 12m |
|
Company Name: |
FluoGuide |
|
Closing: |
January 2020 |
|
Investor: |
Institutional investors & selected HNI’s |
|
TC Advisory: |
Translution Capital acted as financial advisor to FluoGuide (Publ.) in a directed share issue to institutional investors and selected HNI’s |
|
Transaction Size: |
EUR 9.3m |
|
Company Name: |
Tamigo |
|
Closing: |
December 2019 |
|
Investor: |
Viking Ventures |
|
TC Advisory: |
Translution Capital acted as sole financial advisor to Tamigo in relation to the sale of minority stakes combined with a share issue to Viking Venture |
|
Transaction Size: |
SEK 7m |
|
Company Name: |
CombiGene |
|
Closing: |
November 2019 |
|
Investor: |
Institutional investors |
|
TC Advisory: |
Translution Capital acted as exclusive financial advisor to CombiGene, the listed Swedish gene therapy company in the bridge financing by Institutional investors |
|
Transaction Size: |
SEK 20m |
|
Company Name: |
CLS |
|
Closing: |
June 2019 |
|
Investor: |
Institutional investors |
|
TC Advisory: |
Translution Capital acted as exclusive financial advisor to CLS, the listed Swedish cancer ablation company in the bridge financing by Institutional investors |
|
Transaction Size: |
NOK 42m |
|
Company Name: |
5th Planet Games |
|
Closing: |
March 2019 |
|
Investor: |
Institutional investors |
|
TC Advisory: |
Translution Capital acted as sole financial advisor to 5th Planet Games in relation to the directed issue |
|
Transaction Size: |
SEK 36m |
|
Company Name: |
Expres2ion Biotech |
|
Closing: |
March 2019 |
|
Investor: |
Institutional investors |
|
TC Advisory: |
Translution Capital acted as exclusive financial advisor to Nasdaq First North company, Expres2ion Biotechnologies in the directed issue to Institutional investors |
|
Transaction Size: |
Non-disclosed |
|
Company Name: |
Conscia Danmark A/S |
|
Closing: |
March 2019 |
|
Acquirer: |
NA |
|
TC Advisory: |
Translution Capital acted as exclusive financial advisor to the owners of Conscia Danmark A/S in relation to a trade sale of the company |
|
Transaction Size: |
Non-disclosed |
|
Company Name: |
DCR Solutions |
|
Closing: |
December 2018 |
|
Investor: |
KMD Ventures and a consortium of Business Angels |
|
TC Advisory: |
Translution Capital acted as sole financial advisor to DCR Solutions in relation to the capital raise led by KMD Ventures and a consortium of Business Angels |
|
Transaction Size: |
USD 8.5m |
|
Company Name: |
Evaxion |
|
Closing: |
November 2018 |
|
Investor: |
Indonesian investor and 9 Danish Family Offices and Business angels |
|
TC Advisory: |
Translution Capital acted as sole advisor to Evaxion in relation to the capital raise led by an Indonesian investor and 9 Danish Family Offices and Business Angels |
|
Transaction Size: |
Non-disclosed |
|
Company Name: |
Ordrestyring.dk |
|
Closing: |
August 2018 |
|
Acquirer: |
Adelis Equity Partners |
|
TC Advisory: |
Translution Capital acted as financial advisor to the owners of Ordrestyring.dk in relation to a majority sale of the company to Adelis Equity Partners |
|
Transaction Size: |
Non-disclosed |
|
Company Name: |
Nordic Impact Funds |
|
Closing: |
June 2018 |
|
Investor: |
Institutional investors |
|
TC Advisory: |
Translution Capital acted as exclusive financial advisor to Nordic Impact Funds in the close of their first fund |
|
Transaction Size: |
DKK 35m |
|
Company Name: |
EuroInvestor |
|
Closing: |
March 2018 |
|
Investor: |
High Networth Individuals |
|
TC Advisory: |
Translution Capital acted as exclusive financial advisor to EuroInvestor in the fund-raising process led by several High Networth Individuals |
|
Transaction Size: |
Non-disclosed |
|
Company Name: |
Rødbillet.dk |
|
Closing: |
June 2017 |
|
Acquirer: |
Flixbus |
|
TC Advisory: |
Translution Capital acted as sole financial advisor to Rødbillet.dk in relation to the sale of 100% of the company to Flixbus, the German bus transportation company |
|
Transaction Size: |
SEK 35m |
|
Company Name: |
Saniona |
|
Closing: |
May 2017 |
|
Investor: |
Institutional investors |
|
TC Advisory: |
Translution Capital acted as joint bookrunner in the directed issue in Saniona on Nasdaq First North, led by Institutional investors |
|
Transaction Size: |
Non-disclosed |
|
Company Name: |
Shobr |
|
Closing: |
October 2016 |
|
Investor: |
A consortium of Danish Business Angels |
|
TC Advisory: |
Translution Capital acted as sole financial advisor to Shobr in relation to the capital raise led by a consortium of Danish Business Angels |
|
Transaction Size: |
Undisclosed |
The Translution Capital team
Founding Partner
Troels Fellov Larsen
Troels Fellov Larsen
Founding Partner
About
Mr. Fellov has been the founding Partner of Translution Capital since 2013. Mr. Fellov is responsible for the strategic development and continued expansion of the firm’s Corporate Finance business, including sourcing and executing both domestic and International transactions across sectors, sizes, geographies and products.
Mr. Fellov offers over twenty-five years of corporate finance experience through a diverse background within Mergers and Acquisitions, Equity and Debt financing activities. Mr. Fellov has successfully completed over four-hundred transactions representing 20+ billion Euros of enterprise value as trusted advisor for both privately held and large multinational public companies, financial institutions, governments and public authorities, board of directors and special committees.
Previously, Mr. Fellov acted as e.g. Managing Director at SEB Enskilda, Corporate Finance, Executive Director at Carnegie, Corporate Finance, Executive Director at J.P. Morgan, Equity Capital Markets (ECM) and Global Head of Equity Capital Market (ECM) at Nordea Investment Banking – working out of London, Stockholm and Copenhagen.
Troels is a State Authorized Public Accountant and holds a Master of Science in Accounting and Auditing from Copenhagen Business School.
Partner
Jakob Schmidt
Jakob Schmidt
Partner
About
Mr. Schmidt has a background in investment banking, he has e.g. served as Head of ECM at the Nordic corporate finance advisor, Carnegie. Most recently he served as CEO in Exruptive. Prior to that he was SVP at Falck and before that CEO in Pharmexa. He sits on the board of LINX and was formerly member of the board of directors in DIRF, the Danish Investor Relations Society, chairman of the board of directors in Gudme Raaschou Vision, chairman of the board of Directors in Curalogic, chairman of the board of directors in GemVax and Pharmexa Inc.
Mr. Schmidt has obtained his master’s degree in Economics and Business Administration from Copenhagen Business School.
Analyst
Johan Alexander Degn
Johan Alexander Degn
Analyst
About
The day-to-day activities of Mr. Degn entail ECM and M&A project execution, including preparation of investor material, market research, financial modelling, and investor contact.
Prior to joining Translution Capital, Mr. Degn worked as an Equity Analyst with Danske Bank.
Mr. Degn holds a master’s degree in Applied Economics and Finance, and a bachelor’s degree in International Business, both earned from Copenhagen Business School. His master’s included an exchange semester at EDHEC Business School (France).
Founded on a hard working culture and the ability to attract top talent
AN INDEPENDENT ADVISORY OFFERING
Client first always
Our approach is simple: A relentless client commitment. At Translution Capital, we all believe in dedication without compromise.
Extensive experience
Our extensive experience across sectors, geographies and transaction sizes is vital for us to create the best possible solutions.
Independence
We pride ourselves of an operation fully independent and free of any conflict of interest, bureaucracy and over-complexity of products.
We are located in central Copenhagen
Where you can find us
Copenhagen office
Christian IX Gade 10, Floor 04
1111 Copenhagen K
Denmark